Selenium Nanoparticle-Delivered MDM2 Inhibitor Reactivates p53 (PRJCA045316)
This project aims to develop selenium nanoparticles loaded with an MDM2-targeting peptide (Se@MI) for colorectal cancer therapy. Se@MI restores p53 tumor suppressor activity and modulates the tumor immune microenvironment, enhancing CD8+ T cell infiltration while reducing regulatory T cells. Transcriptomic, flow cytometry, and histopathology studies confirm its antitumor efficacy and safety.